The project's goal is to refine antemortem diagnosis of frontotemporallobar degeneration (FTLD) andrelated disorders by distinguishing them from Alzheimer's disease (AD), by improving early diagnosis and bydifferentiating patients with ubiquitin inclusions from those with tau inclusions. By the end of year 10 of thePPG this project will have obtained novel assessment on 107 AD, 131 FTD, 67 SD, 56 PNFA, 43 CBD, 30PSP, 59 ALS, and 89 controls. Neuropathology will be completed in 37 AD, 64 FTD, 25 SD, 23 PNFA, 23CBD, 23 PSP and 27 ALS patients. By exploring clinical pathological correlates in these populations theproject will accomplish the following aims: 1. Refine diagnostic approaches to FTD, PNFA, SD, CBD, andPSP in order to improve separation of these patient groups during life from patients with AD.
This aim will befacilitated by the use of amyloid imaging with the Pittsburgh-compound-B (PIB). Also, genomics andproteomics will be preliminarily explored as tools for differential diagnosis of FTD, PNFA, SD, CBD and PSPfrom each other, and from AD. 2. Explore the earliest changes in FTD patients with a clinical dementia rating(CDR) score of 0.5, and ALS patients (many will have early FTD).
This aim will be tested using novelparadigms that capture social, emotional and imaging domains through the Clinical and Administrative Coreand in projects 2, 3 and 4. Also, genomics and proteomics will be explored as potential markers of earlyFTD or FTD-ALS. 3. Identify syndromes that best predict FTLD-T vs. FTLD-U as defined at pathology.
The aim will be performed by analyzing data collected through the Clinical and Administrative Core and projects 2and 3. Also, genomic and proteomic profiles will be explored in these populations.
Showing the most recent 10 out of 607 publications
